Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10
- Stem cells
- Technical Know How
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203318
IHD means ischemic heart disease. PAD means peripheral arterial disease or any other use with the exception of IHD. Angiogenesis means stimulation of new blood vessel growth in the context of cardiovascular disease.
IPSCIO Record ID: 260407
The licenses granted in this paragraph is exclusive with respect to the Field only.
IPSCIO Record ID: 260408
IPSCIO Record ID: 29073
IPSCIO Record ID: 5858
Cardio Vascu-Grow Human Fibroblast Growth Factor-1 treat patients with advanced atherosclerotic disease of their coronary arteries. This treatment, which regenerates new blood vessels in the hearts of these patients. Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoproteins (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoproteins (HDL), (see apoA-1 Milano).
Issued US Patents
1. U.S. 6,268,178 entitled â€œPhage-Dependent Super-Production of Biologically Active Protein and Peptides;â€ and
2. U.S. 6,642,026 entitled â€œMethod of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.â€
3. U.S. 6,773,899 entitled â€œPhage-Dependent Super-Production of Biologically Active Protein and Peptidesâ€;
4. U.S. 6,794,162, entitled â€œPhage-Dependent Super-Production of Biologically Active Protein and Peptides;â€
Pending US Patent Applications 1.. U.S. 10/649,480 entitled â€œMethod of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis;â€ published as US Patent Application No. US 2004/0115769
IPSCIO Record ID: 3533
The patents relate to certain gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia.
The Licensor intellectual property and research involves gene therapy technologies.
IPSCIO Record ID: 28042
IPSCIO Record ID: 263767
GDNF Product means any Gene Therapy product capable of delivering GDNF or the gene encoding GDNF, or in either case any fragment of GDNF that has Functional Activity.
Based on the promising early results of GDNF gene therapy product in Parkinsonâ€™s disease models, Licensee believe there is an opportunity for a similar approach in other debilitating CNS disorders.
IPSCIO Record ID: 104737
IPSCIO Record ID: 233425
Injection Catheter means the injection catheter known as the Stilettoâ„¢ manufactured by Licensor, including improvements, modifications and replacements thereto.
Product means a plasmid DNA, drug, biologic or other composition comprising VEGF-2. Product does not include any delivery device, including without limitation the Injection Catheter, a hypodermic needle or stent, or the combination of any such plasmid DNA, drug, biologic or other composition with any such delivery device.
VEGF-2 means the Human Genome Sciences angiogenic agent licensed to and being further developed and modified by the Company, sometimes referred to as Vascular Endothelial Growth Factor 2 plasmid DNA, and any modifications or improvements thereto.